Gregory G Schwartz Selected Research

LDL Lipoproteins (beta Lipoproteins)

11/2018	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
6/2009	Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gregory G Schwartz Research Topics

Disease

83	Acute Coronary Syndrome 10/2022 - 01/2001
44	Myocardial Infarction 10/2022 - 01/2002
24	Unstable Angina 10/2022 - 09/2002
24	Stroke (Strokes) 01/2021 - 01/2002
20	Coronary Disease (Coronary Heart Disease) 10/2022 - 07/2004
17	Ischemic Stroke 10/2022 - 11/2012
17	Type 2 Diabetes Mellitus (MODY) 01/2021 - 09/2013
14	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 06/2009
14	Myocardial Ischemia (Ischemic Heart Diseases) 01/2017 - 01/2001
9	Heart Failure 01/2022 - 06/2011
9	Inflammation (Inflammations) 11/2019 - 09/2003
9	Insulin Resistance 01/2018 - 02/2010
8	Dyslipidemias (Dyslipidemia) 01/2022 - 09/2005
7	Atherosclerosis 01/2021 - 03/2013
7	Transient Ischemic Attack 10/2018 - 05/2011
7	Heart Arrest (Cardiac Arrest) 01/2017 - 01/2001
5	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 02/2017
5	Ischemia 01/2020 - 05/2003
5	Cerebrovascular Disorders (Cerebrovascular Occlusion) 12/2019 - 04/2016
5	Atherosclerotic Plaque (Atheroma) 01/2018 - 09/2004
5	Hypertension (High Blood Pressure) 01/2018 - 10/2005
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2013 - 10/2005
3	Atrial Fibrillation 01/2022 - 05/2011
3	Peripheral Arterial Disease 01/2022 - 01/2020
3	Thrombosis (Thrombus) 01/2020 - 06/2009
3	Prediabetic State (Prediabetes) 01/2020 - 07/2015
3	Obesity 01/2018 - 02/2010
3	Ventricular Fibrillation 01/2017 - 05/2003
3	Infarction (Infarctions) 05/2006 - 01/2001
2	Hemorrhagic Stroke 12/2019 - 09/2002
2	Diabetes Mellitus 01/2018 - 05/2017
2	Edema (Dropsy) 01/2018 - 04/2016
2	Weight Gain 01/2018 - 04/2016
2	Muscular Diseases (Myopathy) 09/2014 - 06/2011
1	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 01/2022
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2021
1	Cognitive Dysfunction 01/2021

Drug/Important Bio-Agent (IBA)

49	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 01/2001
31	alirocumabIBA 10/2022 - 11/2014
21	Atorvastatin (Lipitor)FDA Link 01/2022 - 01/2001
18	LDL CholesterolIBA 10/2022 - 01/2001
18	CholesterolIBA 12/2020 - 01/2001
16	oxidized low density lipoproteinIBA 10/2022 - 07/2004
15	omega-Chloroacetophenone (Mace)IBA 10/2022 - 01/2019
12	Lipoproteins (Lipoprotein)IBA 08/2022 - 09/2012
11	Lipoprotein(a)IBA 01/2022 - 09/2004
10	HDL CholesterolIBA 01/2020 - 10/2005
9	Proprotein Convertase 9IBA 08/2022 - 11/2018
8	aleglitazarIBA 01/2020 - 09/2013
8	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2020 - 05/2003
7	Insulin (Novolin)FDA Link 01/2021 - 02/2010
7	dalcetrapibIBA 01/2020 - 12/2009
6	apabetaloneIBA 01/2021 - 04/2018
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2012
6	HDL LipoproteinsIBA 12/2020 - 05/2005
6	LipidsIBA 04/2018 - 01/2002
6	Pioglitazone (Actos)FDA Link 01/2018 - 12/2014
5	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 02/2010
5	C-Reactive ProteinIBA 11/2019 - 09/2003
4	Pharmaceutical PreparationsIBA 01/2018 - 12/2014
4	2,4-thiazolidinedione (thiazolidinedione)IBA 12/2014 - 05/2003
3	ApolipoproteinsIBA 08/2022 - 11/2018
3	Rosuvastatin Calcium (Crestor)FDA Link 01/2022 - 07/2004
3	Monoclonal AntibodiesIBA 01/2022 - 11/2014
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 06/2009
3	Phospholipids (Phosphatides)FDA LinkGeneric 01/2014 - 09/2004
3	Secretory Phospholipases A2IBA 01/2014 - 02/2012
3	Interleukin-6 (Interleukin 6)IBA 01/2013 - 09/2003
2	Apolipoproteins B (ApoB)IBA 08/2022 - 06/2009
2	Ezetimibe (Zetia)FDA Link 01/2022 - 01/2019
2	Cholesterol Ester Transfer ProteinsIBA 01/2020 - 10/2017
2	varespladibIBA 01/2019 - 01/2014
2	LDL Lipoproteins (beta Lipoproteins)IBA 11/2018 - 06/2009
2	CER-001IBA 01/2018 - 02/2017
2	Adenosine Triphosphate (ATP)IBA 01/2017 - 06/2012
2	Triglycerides (Triacylglycerol)IBA 06/2015 - 10/2005
2	CreatinineIBA 09/2014 - 06/2011
2	Phosphotransferases (Kinase)IBA 09/2014 - 06/2011
2	Phospholipases (Phospholipase)IBA 11/2013 - 02/2012
2	SugarsIBA 03/2013 - 02/2010
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2013 - 10/2009
2	Serum Amyloid A Protein (Serum Amyloid A)IBA 01/2013 - 09/2003
2	Antigen-Antibody Complex (Immune Complex)IBA 06/2009 - 09/2004
2	Apolipoprotein B-100 (Apo B 100)IBA 06/2009 - 09/2004
2	1-penicillamyl-Leu(2)- oxytocinIBA 06/2009 - 09/2004
2	PPAR gammaIBA 03/2005 - 05/2003
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022
1	Simvastatin (Zocor)FDA LinkGeneric 01/2022
1	evolocumabIBA 10/2021
1	antineoplaston A10 (A 10)IBA 01/2021
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2021
1	SodiumIBA 01/2021
1	SubtilisinIBA 01/2021
1	ALN-PCSIBA 01/2021

Therapy/Procedure

37	Therapeutics 08/2022 - 07/2004
4	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 05/2006
3	Patient Readmission 07/2004 - 01/2001
2	Subcutaneous Injections 01/2022 - 01/2021
2	Secondary Prevention 11/2019 - 12/2014
2	Percutaneous Coronary Intervention 01/2019 - 05/2006